Volume 24, Number 5—May 2018
Dispatch
Second Human Pegivirus in Hepatitis C Virus–Infected and Hepatitis C Virus/HIV-1–Co-infected Persons Who Inject Drugs, China
Haiying Wang1, Zhengwei Wan1, Qiang Sun1, Nalin Zhu, Tianyi Li, Xuqi Ren, Xiaoping An, Shuyun Deng, Yue Wu, Xiufen Li, Lin Li, Jingyun Li, Yigang Tong, and Shixing Tang
Table 2
Comparison of HPgV and HPgV-2 infections among HCV-, HIV-1–, and HIV-1/HCV–infected populations in Guangdong Province, China*
| Group | No. tested | HPgV-2 Ab+ |
HPgV-2 RNA+ |
HPgV RNA+ |
|||||
|---|---|---|---|---|---|---|---|---|---|
| No. (%) | p value | No. (%) | p value | No. (%) | p value | ||||
| HCV | |||||||||
| + | 178 | 11 (6.2) | <0.001 |
5 (2.8) | 0.026 |
45 (25.3) | 0.130 |
||
| – |
189 |
0 (0) |
0 (0) |
35 (18.5) |
|||||
| HIV-1 | |||||||||
| + | 182 | 10 (5.5) | 0.005 |
4 (2.2) | 0.212 |
60 (33.0) | <0.001 |
||
| – |
185 |
1 (0.5) |
1 (0.5) |
20 (10.8) |
|||||
| HIV-1/HCV | |||||||||
| +/+ | 82 | 10 (12.2) | <0.001 | 4 (4.9) | 0.040 | 32 (39.0) | 0.154 | ||
| +/− | 100 | 0 (0) | 0 (0) | 28 (28.0) | |||||
*p values calculated by using Fisher exact test. Ab, antibodies; HCV, hepatitis C virus; HPgV, human pegivirus; HPgV-2, second human pegivirus; +, positive; –, negative.
1These authors contributed equally to this article.
Page created: April 17, 2018
Page updated: April 17, 2018
Page reviewed: April 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.